查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2086219

兒童疫苗市場：依疫苗類型、疾病、技術、生命週期階段、劑型、最終用戶和年齡層別分類－2026-2032年全球市場預測

Pediatric Vaccines Market by Vaccine Type, Disease, Technology, Lifecycle Stage, Formulation, End User, Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，兒童疫苗市場規模將成長至 797.2 億美元，複合年成長率為 7.62%。

主要市場統計數據
基準年 2025 476.6億美元
預計年份：2026年 509.8億美元
預測年份 2032 797.2億美元
複合年成長率 (%) 7.62%

兒童疫苗市場執行摘要

世界衛生組織（世衛組織）指出，兒童疫苗仍是全球公共衛生領域最具影響力的措施之一，每年可預防約350萬至500萬人死亡。這一市場得益於常規兒童免疫接種計劃，該計劃涵蓋了白喉、破傷風、百日咳、脊髓灰質炎、麻疹、脊髓灰質炎、b型流感嗜血桿菌、肺炎鏈球菌感染、輪狀病毒、兒童乳頭瘤病毒、流感等新疫苗，以及在已獲批准或建議的情況下，瘧疾和呼吸道融合細胞病毒。

兒童疫苗領域的變革性變化

兒童疫苗市場格局正因疾病復發、新型疫苗平台以及對免疫公平性的重新關注而重塑。新冠疫情擾亂了全球常規免疫服務，其恢復進程仍不平衡。世界衛生組織和聯合國兒童基金會報告稱，到2023年，將有1450萬兒童未接種疫苗，因此，市場成長與提高疫苗可及性、開展宣傳活動以及加強基層醫療衛生體系建設密不可分。

人工智慧對兒童疫苗的累積影響

人工智慧（AI）正日益成為兒童疫苗發現、開發、生產、安全監測和供應各個階段的有力驅動力。在研發階段，AI驅動的抗原篩選、蛋白質結構預測、免疫反應建模和臨床試驗最佳化有助於縮短學習週期，並識別出具有更強免疫抗原性原性的候選疫苗。這些工具在兒童族群中尤其重要，因為兒科族群的免疫生物學複雜，且試驗設計必須符合嚴格的安全性和倫理標準。

關於兒童疫苗的關鍵區域見解

亞太地區是兒童疫苗領域最具影響力的地區之一，這得益於其大規模的出生人口、不斷成長的公共免疫預算以及日益壯大的國內生產基地。中國和印度在疫苗的供需兩端都發揮核心作用，而日本、韓國和澳洲則在嚴格的法律規範下維持成熟的免疫規劃。該地區的優先事項包括聯合疫苗、提高肺炎球菌和輪狀病毒疫苗接種率、 人類乳突病毒(HPV)疫苗接種、在流行地區預防日本腦炎以及加強農村和島嶼地區的低溫運輸基礎設施。

兒童疫苗成長的關鍵群體分析

東協兒童疫苗的前景受到收入水平差異、人口稠密的都市區地區、偏遠島嶼地區以及對可靠低溫運輸系統的迫切需求等因素的影響。印尼、越南、泰國、馬來西亞和菲律賓等國繼續優先恢復各自區域的常規免疫接種、登革熱預防策略，並擴大人類乳突病毒（HPV）、肺炎球菌和輪狀病毒疫苗的供應。區域間合作可以提高採購效率、協調監管，並加強應對感染疾病疫情的準備。

主要國家兒童疫苗接種趨勢

美國仍然是兒童疫苗的主要市場，這得益於美國疾病管制與預防中心 (CDC) 的建議、私人保險覆蓋、醫療補助計劃 (Medicaid) 以及兒童疫苗計劃 (VFC)。儘管疫苗接種率的差異和猶豫不決的現象仍然影響著疫苗接種統計數據，但美國仍保持著強大的公共免疫計劃。加拿大透過各省和地區實施，維持健全的公共免疫計劃，並制定了全國統一的疫苗接種指南，確保疫苗接種時間表的一致性。墨西哥致力於恢復常規免疫接種率並加強其採購系統的可靠性，而巴西則透過公共衛生機構，將大規模的公共免疫系統與國內生產能力結合。

為兒童疫苗行業的領導者提供的實用建議

產業領導者應優先考慮兼顧創新與可及性的兒童疫苗策略。製造商可透過投資聯合疫苗、提高熱穩定性、在適當情況下開發無防腐劑配方以及支持快速應對新出現的兒童疾病威脅的可擴展平台來增強自身競爭力。產品系列決策應基於疾病負擔、國家免疫優先事項、衛生經濟學證據和實施可行性。

兒童疫苗分析的調查方法

本執行摘要採用系統化的二手調查方法編寫，重點關注經檢驗的公共衛生、監管和市場資訊來源。主要資訊來源包括世界衛生組織和聯合國兒童基金會的免疫接種率估算、美國疾病控制與預防中心的免疫接種指南、歐洲疾病預防控制中心的監測更新、泛美衛生組織採購和區域免疫資源、全球疫苗免疫聯盟（Gavi）項目資訊、國家免疫規劃、世界銀行人口指標以及來自衛生當局和疫苗研發者的公開資訊。

結論：兒童疫苗是公共衛生領域發展的優先事項。

兒童疫苗市場正步入一個更為複雜且具有重要戰略意義的階段。儘管常規免疫接種仍是基礎，但由於疫苗接種率差異、疾病復發、新型疫苗技術、對供應穩定性的擔憂以及對加強「最後一公里」配送的需求，商業環境正在改變。能夠平衡科學創新與可負擔性、可靠性和實施支持的相關人員，將最有能力創造永續的公共衛生和商業性價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章兒童疫苗市場：依疫苗類型分類

  • 六價疫苗
  • 疫苗單價
  • 五價疫苗
  • 四價疫苗

第8章：兒童疫苗市場：依疾病分類

  • DTP
    • 白喉
    • 百日咳
    • 破傷風
  • B型肝炎
  • Hib
  • 麻疹
  • 肺炎球菌
  • 脊髓灰質炎
  • 輪狀病毒

第9章：兒童疫苗市場：依技術分類

  • 組合型
    • 多醣結合型
    • 蛋白質綴合物
  • 失活
    • 類毒素
    • 病毒性的
  • 減毒活病毒疫苗
    • 細菌
    • 病毒性的
  • 重組
    • 哺乳動物細胞培養
    • 酵母衍生的
  • 次單元
    • 胜肽次單元
    • 蛋白質次單元

第10章：兒童疫苗市場：依生命週期階段分類

  • 市售
  • 贊同
  • 第三階段
  • 臨床前和早期臨床階段

第11章：兒童疫苗市場：以劑型分類

  • 液體
  • 冷凍乾燥

第12章：兒童疫苗市場：依最終用戶分類

  • 診所
    • 一般診所
    • 專科診所
  • 醫院
    • 私立醫院
    • 公立醫院
  • 疫苗接種中心
  • 藥局
    • 醫院藥房
    • 零售藥房

第13章：兒童疫苗市場：依年齡層別分類

  • 青春期
  • 孩子們
  • 嬰兒
  • 新生
  • 嬰兒

第14章兒童疫苗市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第15章：兒童疫苗市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章兒童疫苗市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第18章：公司簡介

  • AJ Vaccines A/S
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bharat Biotech International Limited
  • Biological E. Limited
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Limited
  • Daiichi Sankyo Company, Ltd.
  • Emergent BioSolutions Inc.
  • EuBiologics Co., Ltd.
  • GC Biopharma Corp.
  • GSK plc
  • Haffkine Bio-Pharmaceutical Corporation Ltd.
  • Indian Immunologicals Limited
  • Johnson & Johnson
  • LG Chem Ltd.
  • Merck Sharp & Dohme LLC
  • Mitsubishi Tanabe Pharma Corporation
  • Moderna, Inc.
  • Novavax, Inc.
  • Panacea Biotec Ltd.
  • Pfizer Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • SK Bioscience Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Valneva SE
  • Xiamen Innovax Biotech Co., Ltd.
Product Code: MRR-030EE4851566

The Pediatric Vaccines Market is projected to grow by USD 79.72 billion at a CAGR of 7.62% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 47.66 billion
Estimated Year [2026] USD 50.98 billion
Forecast Year [2032] USD 79.72 billion
CAGR (%) 7.62%

Pediatric Vaccines Market Executive Summary

Pediatric vaccines remain one of the highest-impact interventions in global public health, preventing an estimated 3.5 million to 5 million deaths every year, according to the World Health Organization. The market is anchored by routine childhood immunization programs covering diphtheria, tetanus, pertussis, polio, measles, hepatitis B, Haemophilus influenzae type b, pneumococcal disease, rotavirus, human papillomavirus, influenza, and newer vaccines against malaria and respiratory syncytial virus where approved or recommended.

Demand is shaped by birth cohorts, national immunization schedules, public procurement, pediatric disease burden, cold-chain readiness, vaccine confidence, and access to primary care. WHO and UNICEF estimates show global DTP3 coverage at 84% in 2023, still below the pre-pandemic level and leaving millions of children under-immunized. This coverage gap keeps pediatric vaccine investment central to healthcare resilience, especially as measles outbreaks, pertussis resurgences, and climate-linked disease shifts increase the urgency for strong childhood vaccination systems.

For manufacturers, governments, distributors, and healthcare providers, the pediatric vaccines landscape is moving from volume-led supply toward evidence-led, digitally enabled, equity-focused immunization. Competitive advantage increasingly depends on reliable manufacturing, combination vaccine innovation, regional partnerships, pharmacovigilance strength, affordability strategies, and the ability to support last-mile delivery in both high-income and resource-constrained settings.

Transformative Shifts in the Pediatric Vaccines Landscape

The pediatric vaccines landscape is being reshaped by the convergence of disease resurgence, new vaccine platforms, and renewed attention to immunization equity. The pandemic disrupted routine immunization services worldwide, and the recovery remains uneven. WHO and UNICEF reported 14.5 million zero-dose children in 2023, emphasizing that market growth is inseparable from access expansion, catch-up campaigns, and stronger primary healthcare systems.

Combination vaccines are gaining strategic importance because they reduce the number of injections, improve adherence to pediatric schedules, and simplify logistics for providers. At the same time, next-generation technologies, including mRNA, recombinant protein, viral vector, conjugate, and adjuvanted platforms, are expanding the pediatric pipeline. New approvals and recommendations for malaria vaccines and RSV prevention are also broadening the definition of pediatric immunization beyond long-established antigens.

Procurement is also shifting. Governments and pooled purchasing agencies are placing greater emphasis on supply security, local or regional manufacturing, transparent pricing, and diversified sourcing. This is especially relevant for vaccines requiring complex production, such as pneumococcal conjugate vaccines and combination pediatric vaccines. As a result, market leaders are prioritizing capacity expansion, technology transfer, and partnerships with public health institutions to reduce exposure to supply shocks.

Cumulative Impact of Artificial Intelligence on Pediatric Vaccines

Artificial intelligence is becoming a practical enabler across pediatric vaccine discovery, development, manufacturing, safety monitoring, and delivery. In research and development, AI-supported antigen selection, protein structure prediction, immune-response modeling, and clinical trial optimization can shorten learning cycles and help identify vaccine candidates with stronger immunogenicity profiles. These tools are particularly valuable for pathogens with complex immune biology and for pediatric populations where trial design must meet strict safety and ethical standards.

In manufacturing and supply chain operations, AI can improve demand forecasting, batch-quality monitoring, cold-chain risk detection, and inventory allocation. Pediatric vaccines are highly sensitive to stockouts because missed windows in childhood immunization schedules can create long-term immunity gaps. AI-driven forecasting that integrates birth data, historical coverage, disease surveillance, weather patterns, and clinic-level consumption can help ministries of health and suppliers allocate doses more accurately.

AI also strengthens pharmacovigilance and vaccine confidence when used responsibly. Natural language processing can help identify safety signals from adverse-event databases, call centers, and clinical notes, while digital listening tools can detect misinformation trends that may affect parental decisions. However, AI adoption must be governed by transparent validation, privacy protection, bias mitigation, and human clinical oversight to ensure that algorithmic tools support, rather than replace, evidence-based pediatric immunization decisions.

Key Regional Insights Across Pediatric Vaccines

Asia-Pacific represents one of the most influential pediatric vaccine regions because of its large birth cohorts, expanding public immunization budgets, and growing domestic manufacturing base. China and India play central roles in both demand and supply, while Japan, South Korea, and Australia maintain mature immunization programs with strong regulatory oversight. Regional priorities include combination vaccines, pneumococcal and rotavirus coverage, HPV vaccination, Japanese encephalitis prevention in endemic areas, and stronger cold-chain infrastructure across rural and island geographies.

North America is characterized by broad pediatric vaccine availability, established reimbursement pathways, and strong public health guidance from agencies such as the CDC and the Public Health Agency of Canada. The United States Vaccines for Children program remains a major access mechanism for eligible children, while Canada's provincial and territorial programs support routine immunization. The region's key challenge is not product availability but persistent disparities in coverage, parental hesitancy, and localized outbreaks of vaccine-preventable diseases.

Latin America has historically benefited from PAHO's Revolving Fund, which supports pooled vaccine procurement and access across the region. However, several countries experienced declines in routine immunization coverage after the pandemic, increasing the risk of measles, diphtheria, and pertussis outbreaks. Brazil and Mexico remain major demand centers, while regional recovery depends on catch-up campaigns, primary care strengthening, and renewed investment in surveillance.

Europe combines high regulatory standards with uneven vaccine confidence across countries. The European Union supports coordinated disease surveillance and procurement mechanisms, while national immunization technical advisory groups shape pediatric schedules. Recent measles activity reported across the region underscores the need to close subnational coverage gaps and maintain the 95% two-dose measles vaccination threshold recommended for outbreak prevention.

The Middle East shows a dual market structure. GCC countries generally maintain well-funded pediatric immunization programs, advanced healthcare infrastructure, and rapid adoption of selected new vaccines, while conflict-affected settings face service interruptions and cold-chain constraints. Africa remains central to global immunization equity, with Gavi-supported programs, malaria vaccine rollout in eligible countries, and ongoing efforts to reach zero-dose children. The region offers long-term growth potential, but success depends on financing continuity, local manufacturing initiatives, and last-mile delivery capacity.

Key Group Insights for Pediatric Vaccine Growth

ASEAN's pediatric vaccine outlook is shaped by diverse income levels, dense urban populations, remote island communities, and a strong need for resilient cold-chain systems. Countries such as Indonesia, Vietnam, Thailand, Malaysia, and the Philippines continue to prioritize routine immunization recovery, dengue prevention strategies where applicable, and expanded access to HPV, pneumococcal, and rotavirus vaccines. Regional cooperation can improve procurement efficiency, regulatory convergence, and outbreak preparedness.

The GCC represents a high-value pediatric vaccines group due to strong public healthcare investment, high digital health adoption, and government-led prevention strategies. Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman typically maintain comprehensive childhood immunization schedules and are well positioned to adopt advanced vaccines where supported by health technology assessment and national disease burden data.

The European Union is a regulatory and policy anchor for pediatric vaccines, with the European Medicines Agency, ECDC surveillance, and joint procurement experience supporting coordinated action. While immunization schedules remain nationally determined, EU-level cooperation improves safety monitoring, outbreak response, and evidence generation. The group's main priority is sustaining confidence and closing coverage gaps among underserved and mobile populations.

BRICS countries are strategically important because they combine large pediatric populations, expanding healthcare investment, and significant vaccine manufacturing capabilities. China, India, Brazil, Russia, and South Africa influence global supply security, technology transfer, and affordable vaccine access. The G7 remains a major source of vaccine innovation, financing, regulatory leadership, and global health funding, while NATO countries increasingly view vaccine supply chains, biodefense, and health system resilience as part of broader security preparedness.

Key Country Insights in Pediatric Vaccines

The United States remains a leading pediatric vaccines market, supported by CDC recommendations, private insurance coverage, Medicaid, and the Vaccines for Children program, though coverage disparities and hesitancy continue to affect uptake. Canada maintains strong public immunization programs through provincial and territorial delivery, with national guidance supporting schedule consistency. Mexico is focused on restoring routine coverage and strengthening procurement reliability, while Brazil combines a large public immunization system with domestic production capabilities through public health institutes.

In Europe, the United Kingdom has a long-standing national immunization program and strong surveillance infrastructure, while Germany, France, Italy, and Spain represent major markets shaped by national recommendations, reimbursement, and public confidence dynamics. France has strengthened childhood vaccine requirements in recent years, Germany emphasizes Standing Committee on Vaccination guidance, and Italy and Spain continue to address regional coverage variation. Russia maintains domestic vaccine production capacity and a large pediatric population, with demand influenced by national schedule priorities and public procurement.

In Asia-Pacific, China's pediatric vaccine market is supported by a large birth cohort, national immunization planning, and an expanding domestic industry, while India is central to global supply and demand through its Universal Immunization Programme and established production capacity. Japan emphasizes high-quality regulation and schedule-based pediatric prevention, Australia sustains strong coverage through the National Immunisation Program, and South Korea combines advanced healthcare infrastructure with strong public health delivery. Across these countries, growth is tied to combination vaccines, catch-up immunization, HPV expansion, pneumococcal and rotavirus access, and readiness for new pediatric indications.

Actionable Recommendations for Pediatric Vaccine Leaders

Industry leaders should prioritize pediatric vaccine strategies that combine innovation with access. Manufacturers can improve competitiveness by investing in combination vaccines, thermostability improvements, preservative-free presentations where appropriate, and scalable platforms that support rapid response to emerging pediatric threats. Portfolio decisions should be guided by disease burden, national immunization priorities, health economic evidence, and implementation feasibility.

Supply resilience should be treated as a strategic differentiator. Companies and public agencies should diversify suppliers, strengthen regional fill-finish capacity, improve demand forecasting, and maintain transparent allocation plans for constrained products. Partnerships with Gavi, UNICEF, PAHO, national ministries of health, and regional manufacturers can support more predictable supply and broader market access.

Commercial and public health teams should invest in evidence-based vaccine confidence programs. Pediatric vaccination decisions are strongly influenced by healthcare professionals, parents, community leaders, and digital information environments. Clear safety communication, active pharmacovigilance, culturally relevant outreach, and integration with maternal and child health services can improve acceptance and reduce missed opportunities.

Digital transformation should focus on measurable immunization outcomes. AI-enabled forecasting, electronic immunization registries, reminder-recall systems, and cold-chain monitoring can increase coverage when supported by privacy safeguards and workforce training. Leaders should also build market access dossiers that demonstrate real-world effectiveness, budget impact, equity benefits, and long-term reductions in healthcare utilization.

Research Methodology for Pediatric Vaccines Analysis

This executive summary is developed using a structured secondary research methodology focused on verified public health, regulatory, and market intelligence sources. Core inputs include WHO and UNICEF immunization coverage estimates, CDC immunization guidance, ECDC surveillance updates, PAHO procurement and regional immunization resources, Gavi program information, national immunization schedules, World Bank demographic indicators, and public disclosures from health authorities and vaccine developers.

The analysis triangulates disease burden, vaccination coverage, birth cohort dynamics, procurement models, technology trends, policy shifts, and regional access factors. Market interpretation emphasizes data consistency, source credibility, recency, and relevance to pediatric vaccine decision-making. Qualitative insights are assessed against observable indicators such as routine immunization recovery, zero-dose child estimates, outbreak patterns, national program expansion, and regulatory developments.

All conclusions are framed to support executive-level planning for manufacturers, suppliers, healthcare providers, investors, and public health stakeholders. The methodology avoids unsupported projections and prioritizes evidence-backed drivers, constraints, and opportunities that can be monitored through official immunization, surveillance, procurement, and regulatory datasets.

Conclusion: Pediatric Vaccines as a Public Health Growth Priority

The pediatric vaccines market is entering a more complex and strategically important phase. Routine immunization remains foundational, yet the operating environment is being transformed by coverage gaps, disease resurgence, new vaccine technologies, supply security concerns, and the need for stronger last-mile delivery. Stakeholders that align scientific innovation with affordability, trust, and implementation support will be best positioned to create durable public health and commercial value.

Regional and country-level differences will continue to define opportunity. High-income markets will emphasize advanced vaccines, confidence-building, and lifecycle management, while emerging markets will prioritize access, financing, cold-chain expansion, and domestic capacity. Across all settings, the central market imperative is clear: pediatric vaccines must reach every child at the right time, with reliable supply, trusted evidence, and resilient delivery systems.

AI, digital registries, and data-driven procurement can accelerate progress, but they must be deployed with transparent governance and measurable public health outcomes. The next stage of market leadership will belong to organizations that can integrate innovation, operational excellence, and equity into a unified pediatric immunization strategy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Pediatric Vaccines Market, by Vaccine Type

  • 7.1. Hexavalent
  • 7.2. Monovalent
  • 7.3. Pentavalent
  • 7.4. Quadrivalent

8. Pediatric Vaccines Market, by Disease

  • 8.1. DTP
    • 8.1.1. Diphtheria
    • 8.1.2. Pertussis
    • 8.1.3. Tetanus
  • 8.2. Hepatitis B
  • 8.3. Hib
  • 8.4. Measles
  • 8.5. Pneumococcal
  • 8.6. Polio
  • 8.7. Rotavirus

9. Pediatric Vaccines Market, by Technology

  • 9.1. Conjugate
    • 9.1.1. Polysaccharide Conjugate
    • 9.1.2. Protein Conjugate
  • 9.2. Inactivated
    • 9.2.1. Toxoid
    • 9.2.2. Viral
  • 9.3. Live Attenuated
    • 9.3.1. Bacterial
    • 9.3.2. Viral
  • 9.4. Recombinant
    • 9.4.1. Mammalian Cell Culture
    • 9.4.2. Yeast Based
  • 9.5. Subunit
    • 9.5.1. Peptide Subunit
    • 9.5.2. Protein Subunit

10. Pediatric Vaccines Market, by Lifecycle Stage

  • 10.1. Commercialized
  • 10.2. Registration
  • 10.3. Phase III
  • 10.4. Preclinical And Early Clinical

11. Pediatric Vaccines Market, by Formulation

  • 11.1. Liquid
  • 11.2. Lyophilized

12. Pediatric Vaccines Market, by End User

  • 12.1. Clinics
    • 12.1.1. General Clinics
    • 12.1.2. Specialty Clinics
  • 12.2. Hospitals
    • 12.2.1. Private Hospitals
    • 12.2.2. Public Hospitals
  • 12.3. Immunization Centers
  • 12.4. Pharmacies
    • 12.4.1. Hospital Pharmacies
    • 12.4.2. Retail Pharmacies

13. Pediatric Vaccines Market, by Age Group

  • 13.1. Adolescents
  • 13.2. Children
  • 13.3. Infants
  • 13.4. Neonates
  • 13.5. Toddlers

14. Pediatric Vaccines Market, by Region

  • 14.1. Asia-Pacific
  • 14.2. North America
  • 14.3. Latin America
  • 14.4. Europe
  • 14.5. Middle East
  • 14.6. Africa

15. Pediatric Vaccines Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Pediatric Vaccines Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025

18. Company Profiles

  • 18.1. AJ Vaccines A/S
  • 18.2. AstraZeneca PLC
  • 18.3. Bavarian Nordic A/S
  • 18.4. Bharat Biotech International Limited
  • 18.5. Biological E. Limited
  • 18.6. BioNTech SE
  • 18.7. CanSino Biologics Inc.
  • 18.8. CSL Limited
  • 18.9. Daiichi Sankyo Company, Ltd.
  • 18.10. Emergent BioSolutions Inc.
  • 18.11. EuBiologics Co., Ltd.
  • 18.12. GC Biopharma Corp.
  • 18.13. GSK plc
  • 18.14. Haffkine Bio-Pharmaceutical Corporation Ltd.
  • 18.15. Indian Immunologicals Limited
  • 18.16. Johnson & Johnson
  • 18.17. LG Chem Ltd.
  • 18.18. Merck Sharp & Dohme LLC
  • 18.19. Mitsubishi Tanabe Pharma Corporation
  • 18.20. Moderna, Inc.
  • 18.21. Novavax, Inc.
  • 18.22. Panacea Biotec Ltd.
  • 18.23. Pfizer Inc.
  • 18.24. Sanofi S.A.
  • 18.25. Serum Institute of India Pvt. Ltd.
  • 18.26. Sinovac Biotech Ltd.
  • 18.27. SK Bioscience Co., Ltd.
  • 18.28. Takeda Pharmaceutical Company Limited
  • 18.29. Valneva SE
  • 18.30. Xiamen Innovax Biotech Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL PEDIATRIC VACCINES MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL PEDIATRIC VACCINES MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL PEDIATRIC VACCINES MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL PEDIATRIC VACCINES MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL PEDIATRIC VACCINES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL PEDIATRIC VACCINES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 25. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 27. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HEXAVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HEXAVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HEXAVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MONOVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MONOVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MONOVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PENTAVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PENTAVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PENTAVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL QUADRIVALENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL QUADRIVALENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL QUADRIVALENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DTP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DTP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DTP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIPHTHERIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIPHTHERIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIPHTHERIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PERTUSSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PERTUSSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PERTUSSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TETANUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TETANUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TETANUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HEPATITIS B MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HEPATITIS B MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HEPATITIS B MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MEASLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEASLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEASLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PNEUMOCOCCAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PNEUMOCOCCAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PNEUMOCOCCAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POLIO MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POLIO MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POLIO MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ROTAVIRUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ROTAVIRUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ROTAVIRUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POLYSACCHARIDE CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POLYSACCHARIDE CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POLYSACCHARIDE CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PROTEIN CONJUGATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PROTEIN CONJUGATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PROTEIN CONJUGATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL INACTIVATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL INACTIVATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL INACTIVATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TOXOID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TOXOID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TOXOID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL LIVE ATTENUATED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL LIVE ATTENUATED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL LIVE ATTENUATED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BACTERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BACTERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BACTERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL VIRAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL VIRAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL VIRAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RECOMBINANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL RECOMBINANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL RECOMBINANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MAMMALIAN CELL CULTURE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL YEAST BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL YEAST BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL YEAST BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PEPTIDE SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PEPTIDE SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PEPTIDE SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PROTEIN SUBUNIT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMMERCIALIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL COMMERCIALIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMMERCIALIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL REGISTRATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL REGISTRATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL REGISTRATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PRECLINICAL AND EARLY CLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PRECLINICAL AND EARLY CLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PRECLINICAL AND EARLY CLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL LIQUID MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL LIQUID MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL LIQUID MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL LYOPHILIZED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL LYOPHILIZED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL LYOPHILIZED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL GENERAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL GENERAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL GENERAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL PRIVATE HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL PUBLIC HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL IMMUNIZATION CENTERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL ADOLESCENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL ADOLESCENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL ADOLESCENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL INFANTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL INFANTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 152. GLOBAL INFANTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEONATES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 154. GLOBAL NEONATES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEONATES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL TODDLERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 157. GLOBAL TODDLERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GLOBAL TODDLERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 182. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 184. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 186. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 188. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 191. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 192. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 193. NORTH AMERICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 198. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 200. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 202. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 204. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 206. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 208. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 209. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 210. LATIN AMERICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPE PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 242. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 243. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 244. MIDDLE EAST PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 257. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 258. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 259. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 260. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 261. AFRICA PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 262. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 263. ASEAN PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 264. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 265. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 266. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 267. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 269. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 270. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 271. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 272. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 280. GCC PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. GCC PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. GCC PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 283. GCC PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 284. GCC PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 285. GCC PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 286. GCC PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 287. GCC PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 288. GCC PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 289. GCC PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 290. GCC PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 291. GCC PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 292. GCC PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 293. GCC PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 296. GCC PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 297. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 299. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 300. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 301. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 302. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 314. BRICS PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 315. BRICS PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. BRICS PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 317. BRICS PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 318. BRICS PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 319. BRICS PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 320. BRICS PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 321. BRICS PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 322. BRICS PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 323. BRICS PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 324. BRICS PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 325. BRICS PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 326. BRICS PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. BRICS PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 328. BRICS PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 329. BRICS PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 330. BRICS PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 331. G7 PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 332. G7 PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 333. G7 PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 334. G7 PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 335. G7 PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 336. G7 PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 337. G7 PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 338. G7 PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 339. G7 PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 340. G7 PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 341. G7 PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 342. G7 PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 343. G7 PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 344. G7 PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 345. G7 PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 346. G7 PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 347. G7 PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 348. NATO PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 349. NATO PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 350. NATO PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 351. NATO PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 352. NATO PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 353. NATO PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 354. NATO PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 355. NATO PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 356. NATO PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 357. NATO PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 358. NATO PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 359. NATO PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 360. NATO PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 361. NATO PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 362. NATO PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 363. NATO PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 364. NATO PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 365. GLOBAL PEDIATRIC VACCINES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 366. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 367. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 368. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 369. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY DTP, 2018-2032 (USD MILLION)
  • TABLE 370. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 371. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY CONJUGATE, 2018-2032 (USD MILLION)
  • TABLE 372. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY INACTIVATED, 2018-2032 (USD MILLION)
  • TABLE 373. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY LIVE ATTENUATED, 2018-2032 (USD MILLION)
  • TABLE 374. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY RECOMBINANT, 2018-2032 (USD MILLION)
  • TABLE 375. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY SUBUNIT, 2018-2032 (USD MILLION)
  • TABLE 376. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY LIFECYCLE STAGE, 2018-2032 (USD MILLION)
  • TABLE 377. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 378. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 379. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 380. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 381. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 382. UNITED STATES PEDIATRIC VACCINES MARKET SIZE, BY AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 383. CANADA PEDIATRIC VACCINES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 384. CANADA PEDIATRIC VACCINES MARKET SIZE, BY VACCINE TYPE, 2018-2032 (USD MILLION)
  • TABLE 385. CANADA PEDIATRIC VACCINES MARKET SIZE, BY DISEASE, 2018-2032 (USD MILLION)
  • TABLE 386. CA